Screener
Regenxbio RGNX G&A
G&A at other companies
Other financials
Where this comes from
Reported directly by Regenxbio in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The source filing: Regenxbio’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:15 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-336725
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Operating Expenses | ||||
| Cost of license and royalty revenues | 1,042 | 5,209 | 12,116 | 8,645 |
| Research and development | 56,086 | 59,500 | 113,425 | 112,587 |
| General and administrative | 21,616 | 19,883 | 42,922 | 40,230 |
| Other operating expenses | 12 | 45 | 48 | 60 |
| Total operating expenses | 78,756 | 84,637 | 168,511 | 161,522 |
| Income (loss) from operations | 29,263 | (63,278) | (54,099) | (51,151) |
| Other Income (Expense) |
Item 1. Financial Statements.
FAQ
- What is Regenxbio's G&A?
- Regenxbio (RGNX) reported G&A of $21.62M in Q2 2026.
- How has Regenxbio's G&A changed year-over-year?
- Regenxbio's G&A increased by 8.7% year-over-year, from $19.88M to $21.62M.
- What is the long-term trend for Regenxbio's G&A?
- Over 4 years (2021 to 2025), Regenxbio's G&A has grown at a 1.1% compound annual growth rate (CAGR), from $79.33M to $82.86M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.
Ask your AI about Regenxbio's g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude